IMUX

Immunic (IMUX)

About Immunic (IMUX)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Details

Daily high
$1.29
Daily low
$1.19
Price at open
$1.19
52 Week High
$1.51
52 Week Low
$0.51
Market cap
152.6M
Dividend yield
0.00%
Volume
2.5M
Avg. volume
3.2M
P/E ratio
-1.57

Immunic News

Details

Daily high
$1.29
Daily low
$1.19
Price at open
$1.19
52 Week High
$1.51
52 Week Low
$0.51
Market cap
152.6M
Dividend yield
0.00%
Volume
2.5M
Avg. volume
3.2M
P/E ratio
-1.57